CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IDL Biotech AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IDL Biotech AB
Karlsbodavagen 39
Phone: +46 87996750p:+46 87996750 Bromma, 168 67  Sweden Fax: +46 87999320f:+46 87999320
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
IDL Biotech AB is a Sweden-based company that develops, manufactures and markets in vitro diagnostic (IVD) products for the healthcare sector. The Company’s products are divided into two main areas, namely Oncology and Bacteriology. Oncology includes in vitro tumor markers for various for a number of types of cancer, such as breast, lung, prostate, bladder and ovarian cancers. The markers indicate ongoing tumor cell activity, giving measurements on changes in tumor behavior, and provide early signals about the course of the disease. Oncology comprises such products as TPS, TPAcyk, UBC and MonoTotal. Bacteriology offers TUBEX TF, an in vitro diagnostic test for detection of typhoid fever (a Salmonella infection).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202112/31/2020Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board JerkerSwanstein 67 5/28/2019 1/1/2003
Chief Executive Officer GunnarWahlberg 12/1/2020
Senior Vice President of Global Sales MartynEales 3/29/2018 3/29/2018
9 additional Officers and Directors records available in full report.

Business Names
Business Name
IDL
IDL B
IDL Biotech AB (publ)
IDLB

General Information
Number of Employees: 18 (As of 3/31/2021)
Outstanding Shares: 102,685,122 (As of 6/30/2021)
Shareholders: 2,077
Stock Exchange: AKT
Fax Number: +46 87999320


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 5, 2024